Condition

HR+/HER2- Early Breast Cancer clinical trials and research

• 6Clinical trials
• 3Countries

Newest HR+/HER2- Early Breast Cancer clinical trials

All recruiting trials (6)

• Personalized coaching to help manage therapy for early breast cancer

  This trial tests whether typology-based coaching helps people with HR+/HER2- early breast cancer stay on ribociclib plus an aromatase inhibitor longer than standard education alone.

  Recruiting at 3 sites Institut fuer Frauengesundheit · Augsburg, Bavaria and 2 other locations · NCT07708571

• Culmerciclib plus aromatase inhibitors for early ER-positive/HER2-negative breast cancer

  This study tests whether adding culmerciclib to endocrine therapy before surgery helps highly proliferative ER-positive/HER2-negative breast cancer patients see a better response.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07616453

• Fovinaciclib with endocrine therapy and HER2 blockade for HR+/HER2+ early breast cancer

  This study tests whether adding fovinaciclib to endocrine therapy and dual HER2 blockade can shrink HR+/HER2+ breast tumors before surgery, with treatment adapted after an early response.

  Recruiting at 3 sites Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Nanjing, Jiangsu and 2 other locations · NCT07616427

• Improving outcomes for women with high‑risk HR+ early breast cancer taking abemaciclib

  This project looks back at medical records to see if women with high‑risk HR+/HER2‑ early breast cancer are still taking abemaciclib six months after they start treatment.

  Recruiting Institut fuer Frauengesundheit · Erlangen, Bavaria · NCT07531693

• See if standardized coaching helps patients stick with abemaciclib

  This study tests whether structured patient coaching helps women with early HR+/HER2- breast cancer take abemaciclib more reliably alongside endocrine therapy.

  Recruiting at 8 sites Institut fuer Frauengesundheit · Esslingen am Neckar, Baden-Wurttemberg and 7 other locations · NCT07521202

• Ribociclib plus hormone therapy for HR+/HER2- early breast cancer in Saudi Arabia

  This study will try to see if adding ribociclib to standard adjuvant hormone therapy is effective and safe for adults in Saudi Arabia with HR+/HER2- early breast cancer.

  Recruiting at 2 sites Novartis · Riyadh and 1 other locations · NCT06797531

Quick answers

How many HR+/HER2- Early Breast Cancer clinical trials are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in Germany (3 trials), China (2 trials), Saudi Arabia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →